LYEL
NASDAQ · Biotechnology
Lyell Immunopharma Inc
$19.33
-0.73 (-3.64%)
Open$19.93
Previous Close$20.06
Day High$20.51
Day Low$19.14
52W High$45.00
52W Low$7.65
Volume—
Avg Volume53.5K
Market Cap468.05M
P/E Ratio—
EPS$-15.41
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+44.6% upside
Current
$19.33
$19.33
Target
$27.95
$27.95
$18.45
$27.95 avg
$35.39
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 47.2K | 627.5K | 107.82M |
| Net Income | -360,783,045 | -4,317,882,187 | -16,079,673 |
| Profit Margin | -762,355.6% | -724,237.8% | -14.9% |
| EBITDA | -362,807,593 | -4,583,340,603 | -19,078,562 |
| Free Cash Flow | — | — | -8,704,547 |
| Rev Growth | -92.5% | -92.5% | +2.1% |
| Debt/Equity | — | — | 0.51 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |